Magnesium for Migraine Prevention: The AAN Grade B Evidence and the 600 mg Protocol

Migraine prophylaxis is dominated by prescription drugs — beta blockers, topiramate, anti-CGRP monoclonals — but several non-prescription options carry usable trial evidence. Magnesium is one of the strongest. The American Academy of Neurology and the American Headache Society 2012 guideline list magnesium as Level B, meaning probably effective for migraine prevention, on the strength of three placebo-controlled randomized trials. The protocol that matters is 600 milligrams of elemental magnesium daily, typically given as magnesium citrate or oxide.

The three trials that anchor the recommendation

Peikert and colleagues 1996 randomized 81 adults with episodic migraine to 600 mg of trimagnesium dicitrate or placebo daily for 12 weeks. Attack frequency fell 41.6 percent in the magnesium arm versus 15.8 percent on placebo, with similar reductions in attack duration and rescue medication use [1]. Pfaffenrath and colleagues 1996 tested 486 mg of magnesium aspartate and found no significant benefit, prompting later analyses suggesting the aspartate form or lower dose explained the discrepancy [2]. Mauskop and Altura, in repeated smaller mechanistic and clinical studies, showed that ionized magnesium deficiency is detectable in a meaningful subset of migraineurs and correlates with response to repletion [3].

Form and dose matter

Magnesium citrate, glycinate, malate, and oxide all reach plasma in measurable quantities; bioavailability differences exist but are not enormous at the 600 mg total elemental dose used in the positive trial. The dose-limiting side effect is osmotic diarrhea, which is more pronounced with magnesium oxide and citrate and milder with magnesium glycinate. Some clinicians divide the daily dose to 300 mg twice daily to improve tolerance. Magnesium L-threonate is sometimes promoted for migraine on the basis of brain penetration, but no migraine RCT has used it.

Mechanism: NMDA, cortical spreading depression, and vasoreactivity

Magnesium is a noncompetitive antagonist at the NMDA glutamate receptor, blocks calcium influx into trigeminal nerve terminals, and modulates cortical spreading depression, the propagating wave of neuronal and glial depolarization implicated in migraine aura [4]. Serum magnesium is a poor marker because most body magnesium is intracellular; ionized magnesium and intraerythrocyte assays correlate better with deficiency, although they are not routinely available. Empirical supplementation does not require prior testing.

Adjuncts: riboflavin 400 mg and CoQ10

The same AAN/AHS guideline lists riboflavin 400 mg per day at Level B and coenzyme Q10 100 mg three times daily at Level C [5]. The three are sometimes stacked, and a randomized trial of a combined magnesium-riboflavin-feverfew formulation found benefit similar to riboflavin alone, suggesting the riboflavin component drives the effect in the combination [6]. There is no evidence that combining magnesium with prescription preventives causes adverse interactions at the doses studied.

Who should consider it, and who should not

Patients with episodic migraine averaging four to fourteen days per month, especially those with menstrual triggers or aura, have the best supporting data. The 2024 American Headache Society position statement reaffirmed magnesium oxide 400 to 600 mg daily as a reasonable first-line nutraceutical [7]. Patients with chronic kidney disease must not self-dose magnesium because impaired renal clearance causes hypermagnesemia, which can be severe. Adults on bisphosphonates, levothyroxine, or fluoroquinolone antibiotics should separate dosing by at least 2 hours to avoid absorption blockade.